Proteus in the World of Proteins: Conformational Changes in Protein Kinases

The 512 protein kinases encoded by the human genome are a prime example of nature's ability to create diversity by introducing variations to a highly conserved theme. The activity of each kinase domain is controlled by layers of regulatory mechanisms involving different combinations of post‐translational modifications, intramolecular contacts, and intermolecular interactions. Ultimately, they all achieve their effect by favoring particular conformations that promote or prevent the kinase domain from catalyzing protein phosphorylation. The central role of kinases in various diseases has encouraged extensive investigations of their biological function and three‐dimensional structures, yielding a more detailed understanding of the mechanisms that regulate protein kinase activity by conformational changes. In the present review, we discuss these regulatory mechanisms and show how conformational changes can be exploited for the design of specific inhibitors that lock protein kinases in inactive conformations. In addition, we highlight recent developments to monitor ligand‐induced structural changes in protein kinases and for screening and identifying inhibitors that stabilize enzymatically incompetent kinase conformations.

[1]  G. Superti-Furga,et al.  Structural Basis for the Autoinhibition of c-Abl Tyrosine Kinase , 2003, Cell.

[2]  S. Harrison,et al.  Crystal structures of c-Src reveal features of its autoinhibitory mechanism. , 1999, Molecular cell.

[3]  F. Hobbs,et al.  Identification of a Novel Inhibitor of Mitogen-activated Protein Kinase Kinase* , 1998, The Journal of Biological Chemistry.

[4]  Stephen K Burley,et al.  A Novel Mode of Gleevec Binding Is Revealed by the Structure of Spleen Tyrosine Kinase* , 2004, Journal of Biological Chemistry.

[5]  J. Mestan,et al.  Allosteric inhibitors of Bcr-abl–dependent cell proliferation , 2006, Nature chemical biology.

[6]  Sung-Hou Kim,et al.  Crystal structure of cyclin-dependent kinase 2 , 1993, Nature.

[7]  Chung F. Wong,et al.  Conformational selection of protein kinase A revealed by flexible‐ligand flexible‐protein docking , 2009, J. Comput. Chem..

[8]  S. Kim,et al.  High-resolution crystal structures of human cyclin-dependent kinase 2 with and without ATP: bound waters and natural ligand as guides for inhibitor design. , 1996, Journal of medicinal chemistry.

[9]  R. Abagyan,et al.  Type-II kinase inhibitor docking, screening, and profiling using modified structures of active kinase states. , 2008, Journal of medicinal chemistry.

[10]  John Kuriyan,et al.  Crystal structure of the Src family tyrosine kinase Hck , 1997, Nature.

[11]  R. Morphy Selectively nonselective kinase inhibition: striking the right balance. , 2010, Journal of medicinal chemistry.

[12]  H. Harada,et al.  Interaction between Hck and HIV-1 Nef negatively regulates cell surface expression of M-CSF receptor. , 2008, Blood.

[13]  J. Adams Activation loop phosphorylation and catalysis in protein kinases: is there functional evidence for the autoinhibitor model? , 2003, Biochemistry.

[14]  K. Ferguson,et al.  Structure-based view of epidermal growth factor receptor regulation. , 2008, Annual review of biophysics.

[15]  Helmut Grubmüller,et al.  Mechanoenzymatics of titin kinase , 2008, Proceedings of the National Academy of Sciences.

[16]  A. Reith,et al.  The Structure of Phosphorylated GSK-3β Complexed with a Peptide, FRATtide, that Inhibits β-Catenin Phosphorylation , 2001 .

[17]  Daniel Rauh,et al.  A new screening assay for allosteric inhibitors of cSrc. , 2009, Nature chemical biology.

[18]  Federico Gago,et al.  In silico activation of Src tyrosine kinase reveals the molecular basis for intramolecular autophosphorylation. , 2004, Journal of molecular graphics & modelling.

[19]  Susan S. Taylor,et al.  Crystal structures of the myristylated catalytic subunit of cAMP‐dependent protein kinase reveal open and closed conformations , 1993, Protein science : a publication of the Protein Society.

[20]  L. Johnson,et al.  The crystal structure of a phosphorylase kinase peptide substrate complex: kinase substrate recognition , 1997, The EMBO journal.

[21]  M. Lamers,et al.  Structure of the protein tyrosine kinase domain of C-terminal Src kinase (CSK) in complex with staurosporine. , 1999, Journal of molecular biology.

[22]  A. Reith,et al.  The structure of MSK1 reveals a novel autoinhibitory conformation for a dual kinase protein. , 2004, Structure.

[23]  D. Gilliland,et al.  Roles of tyrosine 589 and 591 in STAT5 activation and transformation mediated by FLT3-ITD. , 2006, Blood.

[24]  Susan S. Taylor,et al.  Crystal structure of a transition state mimic of the catalytic subunit of cAMP-dependent protein kinase , 2002, Nature Structural Biology.

[25]  E. Krebs Historical perspectives on protein phosphorylation and a classification system for protein kinases. , 1983, Philosophical transactions of the Royal Society of London. Series B, Biological sciences.

[26]  T. Pawson,et al.  Structural Basis for Autoinhibition of the EphB2 Receptor Tyrosine Kinase by the Unphosphorylated Juxtamembrane Region , 2001, Cell.

[27]  S. Steinberg Distinctive activation mechanisms and functions for protein kinase Cdelta. , 2004, The Biochemical journal.

[28]  Tom Alber,et al.  Structure of Mycobacterium tuberculosis PknB supports a universal activation mechanism for Ser/Thr protein kinases , 2003, Nature Structural Biology.

[29]  T. Pawson New impressions of Src and Hck , 1997, Nature.

[30]  John Kuriyan,et al.  Structural Basis for the Inhibition of Tyrosine Kinase Activity of ZAP-70 , 2007, Cell.

[31]  Neil Q. McDonald,et al.  Crystal structure of a γ‐herpesvirus cyclin–cdk complex , 2000 .

[32]  Benoît Roux,et al.  Src Kinase Conformational Activation: Thermodynamics, Pathways, and Mechanisms , 2008, PLoS Comput. Biol..

[33]  Kornelia Polyak,et al.  Mechanism of CDK activation revealed by the structure of a cyclinA-CDK2 complex , 1995, Nature.

[34]  J. Warmus,et al.  Structures of human MAP kinase kinase 1 (MEK1) and MEK2 describe novel noncompetitive kinase inhibition , 2004, Nature Structural &Molecular Biology.

[35]  Bairong Shen,et al.  Genome wide analysis of pathogenic SH2 domain mutations , 2008, Proteins.

[36]  D. Fabbro,et al.  The crystal structure of a c-Src complex in an active conformation suggests possible steps in c-Src activation. , 2005, Structure.

[37]  T. Hunter,et al.  The Protein Kinase Complement of the Human Genome , 2002, Science.

[38]  E. Baker,et al.  Structure and inhibition of the human cell cycle checkpoint kinase, Wee1A kinase: an atypical tyrosine kinase with a key role in CDK1 regulation. , 2005, Structure.

[39]  Nguyen-Huu Xuong,et al.  Crystal structure of the catalytic subunit of cAMP-dependent protein kinase complexed with magnesium-ATP and peptide inhibitor , 1993 .

[40]  J. Walker,et al.  Autoregulation by the juxtamembrane region of the human ephrin receptor tyrosine kinase A3 (EphA3). , 2008, Structure.

[41]  Elizabeth J. Goldsmith,et al.  Activation Mechanism of the MAP Kinase ERK2 by Dual Phosphorylation , 1997, Cell.

[42]  C. Grütter,et al.  Hybrid compound design to overcome the gatekeeper T338M mutation in cSrc. , 2009, Journal of medicinal chemistry.

[43]  Hiroto Yamaguchi,et al.  Structural basis for activation of human lymphocyte kinase Lck upon tyrosine phosphorylation , 1996, Nature.

[44]  B. Keyt,et al.  The crystal structure of vascular endothelial growth factor (VEGF) refined to 1.93 A resolution: multiple copy flexibility and receptor binding. , 1997, Structure.

[45]  T. Pawson,et al.  A change in conformational dynamics underlies the activation of Eph receptor tyrosine kinases , 2006, The EMBO journal.

[46]  Alex Matter,et al.  Glivec (STI571, imatinib), a rationally developed, targeted anticancer drug , 2002, Nature Reviews Drug Discovery.

[47]  M. Teplova,et al.  Crystal structures of the catalytic domain of human protein kinase associated with apoptosis and tumor suppression , 2001, Nature Structural Biology.

[48]  John Kuriyan,et al.  Mechanism for Activation of the EGF Receptor Catalytic Domain by the Juxtamembrane Segment , 2009, Cell.

[49]  J. Kuriyan,et al.  Activation of the Sire-family tyrosine kinase Hck by SH3 domain displacement , 1997, Nature.

[50]  R. Knegtel,et al.  Crystal Structure of Aurora-2, an Oncogenic Serine/Threonine Kinase* , 2002, The Journal of Biological Chemistry.

[51]  A. Kral,et al.  Identification and characterization of pleckstrin-homology-domain-dependent and isoenzyme-specific Akt inhibitors , 2022 .

[52]  G. Alton,et al.  Characterization of the CHK1 allosteric inhibitor binding site. , 2009, Biochemistry.

[53]  Chao Zhang,et al.  The unfolded protein response signals through high-order assembly of Ire1 , 2009, Nature.

[54]  Sibylle Mittnacht,et al.  Trans‐activation of the DNA‐damage signalling protein kinase Chk2 by T‐loop exchange , 2006, The EMBO journal.

[55]  A. Wissner,et al.  The Development of HKI‐272 and Related Compounds for the Treatment of Cancer , 2008, Archiv der Pharmazie.

[56]  E. Estey,et al.  Identification of a novel activating mutation (Y842C) within the activation loop of FLT3 in patients with acute myeloid leukemia (AML). , 2005, Blood.

[57]  Daniel Rauh,et al.  Development of a fluorescent-tagged kinase assay system for the detection and characterization of allosteric kinase inhibitors. , 2009, Journal of the American Chemical Society.

[58]  H. Jäckle,et al.  Mitogen‐activated protein kinases interacting kinases are autoinhibited by a reprogrammed activation segment , 2006, The EMBO journal.

[59]  D. Koshland Application of a Theory of Enzyme Specificity to Protein Synthesis. , 1958, Proceedings of the National Academy of Sciences of the United States of America.

[60]  A. Pozzi,et al.  The juxtamembrane region of the EGF receptor functions as an activation domain. , 2009, Molecular cell.

[61]  K. Wilson,et al.  Structural Basis for the Autoinhibition and STI-571 Inhibition of c-Kit Tyrosine Kinase* , 2004, Journal of Biological Chemistry.

[62]  L. Schmidt,et al.  Structural basis of oncogenic activation caused by point mutations in the kinase domain of the MET proto‐oncogene: Modeling studies , 2001, Proteins.

[63]  D. Morgan,et al.  Protein kinase regulation: insights from crystal structure analysis. , 1994, Current opinion in cell biology.

[64]  F. Lu,et al.  The structural basis for autoinhibition of FLT3 by the juxtamembrane domain. , 2004, Molecular cell.

[65]  N. Gray,et al.  N-Myristoylated c-Abl Tyrosine Kinase Localizes to the Endoplasmic Reticulum upon Binding to an Allosteric Inhibitor* , 2009, The Journal of Biological Chemistry.

[66]  C. Grütter,et al.  Displacement assay for the detection of stabilizers of inactive kinase conformations. , 2010, Journal of Medicinal Chemistry.

[67]  P. Parker,et al.  PKC maturation is promoted by nucleotide pocket occupation independently of intrinsic kinase activity , 2009, Nature Structural &Molecular Biology.

[68]  Martin Peifer,et al.  Chemogenomic profiling provides insights into the limited activity of irreversible EGFR Inhibitors in tumor cells expressing the T790M EGFR resistance mutation. , 2010, Cancer research.

[69]  Chao Zhang,et al.  Inhibitor Hijacking of Akt Activation , 2009, Nature chemical biology.

[70]  E. P. Kennedy,et al.  The enzymatic phosphorylation of proteins. , 1954, The Journal of biological chemistry.

[71]  L. Tsai,et al.  Structure and Regulation of the CDK5-p25nck5a Complex , 2001 .

[72]  L. Johnson The regulation of protein phosphorylation. , 2009, Biochemical Society transactions.

[73]  S. Knapp,et al.  Structure of the Human Protein Kinase MPSK1 Reveals an Atypical Activation Loop Architecture , 2008, Structure.

[74]  K. Longenecker,et al.  Three-dimensional structure of mammalian casein kinase I: molecular basis for phosphate recognition. , 1996, Journal of molecular biology.

[75]  C. Grütter,et al.  Structural insights into how irreversible inhibitors can overcome drug resistance in EGFR. , 2008, Bioorganic & medicinal chemistry.

[76]  P. Jeffrey,et al.  Structural basis of cyclin-dependent kinase activation by phosphorylation , 1996, Nature Structural Biology.

[77]  B. Keyt,et al.  1H, 13C, and 15N backbone assignment and secondary structure of the receptor‐binding domain of vascular endothelial growth factor , 1997, Protein science : a publication of the Protein Society.

[78]  Robert Huber,et al.  The Protein Kinase C Inhibitor Bisindolyl Maleimide 2 Binds with Reversed Orientations to Different Conformations of Protein Kinase A* , 2004, Journal of Biological Chemistry.

[79]  M. Meyerson,et al.  Identifying and characterizing a novel activating mutation of the FLT3 tyrosine kinase in AML. , 2004, Blood.

[80]  B. Druker,et al.  Abl protein-tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-kit and platelet-derived growth factor receptors. , 2000, The Journal of pharmacology and experimental therapeutics.

[81]  R. Copeland,et al.  Drug–target residence time and its implications for lead optimization , 2007, Nature Reviews Drug Discovery.

[82]  Daniel Rauh,et al.  High-throughput screening to identify inhibitors which stabilize inactive kinase conformations in p38alpha. , 2009, Journal of the American Chemical Society.

[83]  N. Gray,et al.  Targeting cancer with small molecule kinase inhibitors , 2009, Nature Reviews Cancer.

[84]  L. Johnson,et al.  The structural basis for specificity of substrate and recruitment peptides for cyclin-dependent kinases , 1999, Nature Cell Biology.

[85]  John Kuriyan,et al.  Crystal structures of the kinase domain of c-Abl in complex with the small molecule inhibitors PD173955 and imatinib (STI-571). , 2001, Cancer research.

[86]  P. Seeburg,et al.  Structural mechanism for STI-571 inhibition of abelson tyrosine kinase. , 2000, Science.

[87]  L. Johnson,et al.  Two structures of the catalytic domain of phosphorylase kinase: an active protein kinase complexed with substrate analogue and product. , 1995, Structure.

[88]  Y. Matsuzawa,et al.  Constitutive activation of c-kit in FMA3 murine mastocytoma cells caused by deletion of seven amino acids at the juxtamembrane domain. , 1996, Blood.

[89]  Mark R Player,et al.  Crystal Structure of the Tyrosine Kinase Domain of Colony-stimulating Factor-1 Receptor (cFMS) in Complex with Two Inhibitors* , 2006, Journal of Biological Chemistry.

[90]  J. Zheng,et al.  Structure of a peptide inhibitor bound to the catalytic subunit of cyclic adenosine monophosphate-dependent protein kinase. , 1991, Science.

[91]  R. V. van Etten,et al.  c-Abl Has High Intrinsic Tyrosine Kinase Activity That Is Stimulated by Mutation of the Src Homology 3 Domain and by Autophosphorylation at Two Distinct Regulatory Tyrosines* , 2000, The Journal of Biological Chemistry.

[92]  Harald Schwalbe,et al.  NMR characterization of kinase p38 dynamics in free and ligand-bound forms. , 2006, Angewandte Chemie.

[93]  Gerard J Kleywegt,et al.  Application and limitations of X-ray crystallographic data in structure-based ligand and drug design. , 2003, Angewandte Chemie.

[94]  C. Grütter,et al.  Fluorophore labeling of the glycine-rich loop as a method of identifying inhibitors that bind to active and inactive kinase conformations. , 2010, Journal of the American Chemical Society.

[95]  Satoru Takeuchi,et al.  Structure of the Carboxyl-terminal Src Kinase, Csk* , 2002, The Journal of Biological Chemistry.

[96]  Susan S. Taylor,et al.  Surface comparison of active and inactive protein kinases identifies a conserved activation mechanism , 2006, Proceedings of the National Academy of Sciences.

[97]  E. Mandelkow,et al.  Structure of the catalytic and ubiquitin-associated domains of the protein kinase MARK/Par-1. , 2006, Structure.

[98]  Stefan Knapp,et al.  Structure of the Pseudokinase VRK3 Reveals a Degraded Catalytic Site, a Highly Conserved Kinase Fold, and a Putative Regulatory Binding Site , 2009, Structure.

[99]  Oliver Hantschel,et al.  Organization of the SH3-SH2 unit in active and inactive forms of the c-Abl tyrosine kinase. , 2006, Molecular cell.

[100]  Chung F. Wong,et al.  The structure of Sky1p reveals a novel mechanism for constitutive activity , 2001, Nature Structural Biology.

[101]  Susan S. Taylor,et al.  Evidence for an internal entropy contribution to phosphoryl transfer: a study of domain closure, backbone flexibility, and the catalytic cycle of cAMP-dependent protein kinase. , 2002, Journal of molecular biology.

[102]  John Kuriyan,et al.  An Allosteric Mechanism for Activation of the Kinase Domain of Epidermal Growth Factor Receptor , 2006, Cell.

[103]  Allan Wissner,et al.  Kinase domain mutations in cancer: implications for small molecule drug design strategies. , 2009, Journal of medicinal chemistry.

[104]  Ming-Li Xiang,et al.  Detailed conformational dynamics of juxtamembrane region and activation loop in c‐Kit kinase activation process , 2008, Proteins.

[105]  G. J. Mulder Ueber die Zusammensetzung einiger thierischen Substanzen , 1839 .

[106]  Chao Zhang,et al.  Bypassing a Kinase Activity with an ATP-Competitive Drug , 2003, Science.

[107]  Liao Jie-Lou Jeffrey and Andrews C. Robert,et al.  Targeting protein multiple conformations: a structure-based strategy for kinase drug design. , 2007 .

[108]  P. Dorrestein,et al.  A sliding docking interaction is essential for sequential and processive phosphorylation of an SR protein by SRPK1. , 2008, Molecular cell.

[109]  G. Müller,et al.  Small-molecule inhibitors binding to protein kinase. Part II: the novel pharmacophore approach of type II and type III inhibition , 2008, Expert opinion on drug discovery.

[110]  K. Spiekermann,et al.  From Kinases to Cancer: Leakiness, Loss of Autoinhibition and Leukemia , 2006, Cell cycle.

[111]  John Kuriyan,et al.  A Src-Like Inactive Conformation in the Abl Tyrosine Kinase Domain , 2006, PLoS biology.

[112]  G. Müller,et al.  Small-molecule inhibitors binding to protein kinases. Part I: exceptions from the traditional pharmacophore approach of type I inhibition , 2008, Expert opinion on drug discovery.

[113]  Ron Diskin,et al.  A novel lipid binding site formed by the MAP kinase insert in p38 alpha. , 2008, Journal of molecular biology.

[114]  L. Johnson Protein kinase inhibitors: contributions from structure to clinical compounds , 2009, Quarterly Reviews of Biophysics.

[115]  L. Pearl,et al.  Structural basis for recruitment of glycogen synthase kinase 3β to the axin—APC scaffold complex , 2003, The EMBO journal.

[116]  P. Bastiaens,et al.  Growth factor-induced MAPK network topology shapes Erk response determining PC-12 cell fate , 2007, Nature Cell Biology.